NHSA (prev. SMIA)

Explore the landscape of NHSA (prev. SMIA) in China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data and insights on NHSA (prev.  SMIA) to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Mabwell to Present Phase II Data for Nectin‑4 ADC 9MW2821 at ESMO 2026 – 30.0% ORR in Post‑TOP1i‑ADC Triple‑Negative Breast Cancer, Headlining Four Phase III Programs
CompanyDrug

Mabwell to Present Phase II Data for Nectin‑4 ADC 9MW2821 at ESMO 2026 – 30.0% ORR in Post‑TOP1i‑ADC Triple‑Negative Breast Cancer, Headlining Four Phase III Programs

Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062; HKG: 2493) announced that it will present, as an oral report, Phase II clinical data for 9MW2821 – its innovative Nectin‑4‑targeted antibody‑drug conjugate…

EMA's CHMP Backs Flexible Dosing for Regeneron's Libtayo – Every‑Six‑Week 700 mg Regimen and Shortened Infusion Options Across All Approved PD‑1 Indications

EMA’s CHMP Backs Flexible Dosing for Regeneron’s Libtayo – Every‑Six‑Week 700 mg Regimen and Shortened Infusion Options Across All Approved PD‑1 Indications

Porton Advanced Solutions Partners with Hangzhou Aisijia Biotech on Diabetes Cell Therapy – CDMO to Provide Process Development, GMP Manufacturing and China IND Filing Support for Autologous Pancreatic Progenitor Cell Program

Porton Advanced Solutions Partners with Hangzhou Aisijia Biotech on Diabetes Cell Therapy – CDMO to Provide Process Development, GMP Manufacturing and China IND Filing Support for Autologous Pancreatic Progenitor Cell Program

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
NHSA and MCA Boost Medical Assistance with Enhanced Information Sharing Measures
Policy / Regulatory

NHSA and MCA Boost Medical Assistance with Enhanced Information Sharing Measures

China's NHSA Sets October Dates for National Reimbursement Drug List Negotiations and Price Bidding
Policy / Regulatory

China’s NHSA Sets October Dates for National Reimbursement Drug List Negotiations and Price Bidding

China's NHSA Concludes Pre-Negotiation Talks for National Reimbursement Drug List
Policy / Regulatory

China’s NHSA Concludes Pre-Negotiation Talks for National Reimbursement Drug List

NHSA Standardizes NRDL Drug Purchases to Combat Prescription Fraud
Policy / Regulatory

NHSA Standardizes NRDL Drug Purchases to Combat Prescription Fraud

China's National Healthcare Security Administration Issues Draft Guidelines for Long-Term Care Insurance
Policy / Regulatory

China’s National Healthcare Security Administration Issues Draft Guidelines for Long-Term Care Insurance

Policy / Regulatory

China Unveils Medical Insurance Eligibility Management System for Designated Healthcare Personnel

Policy / Regulatory

NHSA Concludes 2024 NRDL Review, Announces Submission Deadlines for Drug Manufacturers

Policy / Regulatory

China’s NHSA and MOF Issue Notices to Enhance Cross-Regional Medical Treatment Direct Settlement

Show More